Amoxicillin-sulbactam: A clinical and therapeutic review

Combinations of beta -lactamase inhibitors with penicillins, especially ami nopenicillins, have broad-spectrum antibacterial activity against most of t he common pathogens of the respiratory and urinary tracts. This means that they are an ideal treatment for infections such as otitis media, sinusitis, special cases of pharyngeal tonsillitis (recurring forms, indirect pathoge nic action, or after the failure of amoxicillin monotherapy), acute exacerb ations of chronic bronchitis, cystitis, urethritis, etc. The amoxicillin-sulbactam combination is active against both beta -lactamas e producer and nonproducer strains, and is effective against Gram-positive cocci (Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aur eus of nonhospital origin), Gram-negative cocci (Neisseria gonorrhoeae, Mor axella catarrhalis and others), Gram-negative bacilli (nonhospital strains of Haemophilus influenzae, Escherichia coli and Klebsiella pneumoniae and o thers) and anaerobes. Its antimicrobial activity means that it is indicated in the treatment of respiratory, ear, nose and throat, urinary, dermatolog ical and gynecological infections caused by susceptible germs, as well as i n a variety of surgical situations (both as a treatment and as prophylaxis) . it is absorbed very well orally, and its pharmacokinetic profile is very favorable, with very good tissue penetration. It is reasonably well tolerat ed: in a variable percentage of cases it may cause modification of intestin al transit and/or fecal consistency, which usually abates spontaneously. Th e new formulation for administration at intervals of 12 h is easier to use, is better tolerated and favors completion of therapy. In summary, the amox icillin-sulbactam combination is effective and well tolerated in most infec tions of nonhospital origin in adults and children. (C) 2001 Prous Science. All rights reserved.